Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression.

Journal Article (Clinical Trial;Journal Article)

The authors treated 16 depressed patients with up to 90 mg/day of phenelzine. After acetylation phenotype was determined and platelet monoamine oxidase (MAO) activity measured, no significant relationship was observed between clinical improvement and acetylation phenotype or between MAO inhibition and acetylation. Discrepant findings regarding acetylation phenotype and the effects of phenelzine are discussed. The authors do not recommend a sulfamethazine phenotype test as a predictor of outcome for phenelzine.

Full Text

Duke Authors

Cited Authors

  • Davidson, J; McLeod, MN; Blum, MR

Published Date

  • April 1, 1978

Published In

Volume / Issue

  • 135 / 4

Start / End Page

  • 467 - 469

PubMed ID

  • 345825

International Standard Serial Number (ISSN)

  • 0002-953X

Digital Object Identifier (DOI)

  • 10.1176/ajp.135.4.467


  • eng

Conference Location

  • United States